CN110913884A - 抑制dna依赖蛋白激酶催化亚基的药物 - Google Patents

抑制dna依赖蛋白激酶催化亚基的药物 Download PDF

Info

Publication number
CN110913884A
CN110913884A CN201880046593.1A CN201880046593A CN110913884A CN 110913884 A CN110913884 A CN 110913884A CN 201880046593 A CN201880046593 A CN 201880046593A CN 110913884 A CN110913884 A CN 110913884A
Authority
CN
China
Prior art keywords
endostatin
tumor
cancer
cell
natural human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880046593.1A
Other languages
English (en)
Other versions
CN110913884B (zh
Inventor
罗永章
贾琳
常国栋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Publication of CN110913884A publication Critical patent/CN110913884A/zh
Application granted granted Critical
Publication of CN110913884B publication Critical patent/CN110913884B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

使用血管内皮抑制素联合诱导DNA双链断裂的治疗方案治疗肿瘤或癌症的方法和药物。所述的方法和组合物用于治疗P53功能缺失的肿瘤或癌症，或者P53功能正常的肿瘤或癌症。

Description

PCT国内申请，说明书已公开。

Claims (76)

  1. PCT国内申请，权利要求书已公开。
CN201880046593.1A 2017-07-30 2018-07-27 抑制dna依赖蛋白激酶催化亚基的药物 Active CN110913884B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710638033 2017-07-30
CN2017106380332 2017-07-30
CN201710733900 2017-08-24
CN2017107339000 2017-08-24
PCT/CN2018/097609 WO2019024814A1 (zh) 2017-07-30 2018-07-27 抑制dna依赖蛋白激酶催化亚基的药物

Publications (2)

Publication Number Publication Date
CN110913884A true CN110913884A (zh) 2020-03-24
CN110913884B CN110913884B (zh) 2023-06-06

Family

ID=65233426

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880046593.1A Active CN110913884B (zh) 2017-07-30 2018-07-27 抑制dna依赖蛋白激酶催化亚基的药物

Country Status (7)

Country Link
US (2) US20200237796A1 (zh)
EP (1) EP3662922A4 (zh)
JP (1) JP7492687B2 (zh)
CN (1) CN110913884B (zh)
AU (1) AU2018310410A1 (zh)
CA (1) CA3103035A1 (zh)
WO (1) WO2019024814A1 (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1891717A (zh) * 2005-07-08 2007-01-10 南京大学 内皮抑素的化学修饰方法及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065515A2 (en) 1998-06-15 1999-12-23 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
DE69936141T2 (de) 1998-06-30 2008-01-31 Sloan-Kettering Institute For Cancer Research Verwendung von dna-pk
US7078485B2 (en) 2002-12-05 2006-07-18 Yantai Medgenn Ltd. N-terminal modified recombinant human endostatin and its production
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN102698270B (zh) * 2011-03-28 2016-02-03 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
CN117987505A (zh) 2011-09-09 2024-05-07 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1891717A (zh) * 2005-07-08 2007-01-10 南京大学 内皮抑素的化学修饰方法及其应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
LIN JIA等: "Endostatin sensitizes p53-deficient non-small-cell lung cancer to genotoxic chemotherapy by targeting DNA-dependent protein kinase catalytic subunit", 《JOURNAL OF PATHOLOGY》 *
YAN FU等: "The N-Terminal Integrity Is Critical for the Stability and Biological Functions of Endostatin", 《BIOCHEMISTRY》 *
ZHEN Y YOU等: "The radiosensitization effects of Endostar on human lung squamous cancer cells H-520", 《CANCER CELL INTERNATIONAL》 *
匿名: "NCI-H520 [H520]ATCC HTB-182(TM) Homo sapiens lung squamous c", 《HTTPS://WWW.LGCSTANDARDS-ATCC.ORG/PRODUCTS/ALL/HTB-182.ASPX？GEO_COUNTRY=NL#CHARACTERISTICS》 *
王泽新等: "内皮抑素联合阿霉素治疗鼠H22 肝癌移植瘤研究", 《实用医学杂志》 *
陈建华等: "重组人血管内皮抑制素联合卡铂与依托泊苷治疗晚期小细胞肺癌的临床观察", 《实用临床医药杂志》 *

Also Published As

Publication number Publication date
JP7492687B2 (ja) 2024-05-30
EP3662922A1 (en) 2020-06-10
AU2018310410A1 (en) 2020-03-12
CA3103035A1 (en) 2019-02-07
US20240165140A1 (en) 2024-05-23
CN110913884B (zh) 2023-06-06
EP3662922A4 (en) 2021-04-07
US20200237796A1 (en) 2020-07-30
JP2020528457A (ja) 2020-09-24
WO2019024814A1 (zh) 2019-02-07

Similar Documents

Publication Publication Date Title
Gordon‐Weeks et al. Neutrophils promote hepatic metastasis growth through fibroblast growth factor 2–dependent angiogenesis in mice
Bayo et al. Jumonji inhibitors overcome radioresistance in cancer through changes in H3K4 methylation at double-strand breaks
ES2928111T3 (es) Inhibición de la señalización AXL en terapia antimetastásica
US20210213079A1 (en) Treatment of brain cancer with oncolytic adenovirus
US20160108378A1 (en) Inhibition of AXL Signaling in Anti-Metastatic Therapy
ES2817414T3 (es) Régimen de terapia y métodos para sensibilizar células de cáncer tratadas con una terapia epigenética frente a inhibidores de PARP en múltiples cánceres
US20170106059A1 (en) Reduction of egfr therapeutic toxicity
CN115554405B (zh) 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途
Lin et al. Mithramycin a radiosensitizes EWS: Fli1+ Ewing sarcoma cells by inhibiting double strand break repair
CN110913884A (zh) 抑制dna依赖蛋白激酶催化亚基的药物
JP5393691B2 (ja) 急性ヒト骨髄性白血病細胞を死滅させるトロンボポエチン受容体作用薬（ＴｐｏＲＡ）
US20210023107A1 (en) USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
Pruller et al. A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy
Bhatkar et al. ATM kinase inhibitor KU-55933 contribution in cisplatin mediated HeLa proliferation
US20230151391A1 (en) Nucleic acid construct that can measure homologous recombination activity, and method for using same
Sesink et al. The AsiDNA™ decoy mimicking DSBs protects the normal tissue from radiation toxicity through a DNA-PK/p53/p21-dependent G1/S arrest
JP6969778B2 (ja) 誤りがちｄｎａ修復経路の抑制によるがんの治療
WO2021150770A1 (en) Oncogenic trim37 is a targetable epigenetic driver of metastasis and links chemoresistance and metastatic fate in triple-negative breast cancer
JP6944373B2 (ja) Ｍｃｊアゴニストおよびそれらに関する使用
Xiao et al. Synergistic inhibition of APE1 redox activity and ATM activation sensitizes osteosarcoma cells to ionizing radiation by inducing ferroptosis
JP2024510757A (ja) 炎症細胞または活性化細胞を標的とし、炎症性の状態および疼痛を処置するかまたは改善するための組成物および方法
ES2373151B1 (es) Uso de inhibidores de edg2 para el tratamiento de la artritis reumatoide.
Hiddingh Treatment sensitizers for high-grade brain tumors
Maja Investigation of TRAIL's capacity to cause mutations in surviving cells
Winkles et al. GrB TWEAK: A Potential Novel Biologic for NSCLC Therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant